ABBVIE INC. vs. ARS Pharmaceuticals, Inc. Common Stock
ABBVIE INC. (ABBV) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| ABBV | SPRY | |
|---|---|---|
| Market Cap | $453.19 billion | $558.89 million |
| Revenue (TTM) | $64.39 billion | $116.93 million |
| Net Income (TTM) | $6.32 billion | $-215,432,000 |
ABBV leads on 3 of 3 size & scale factors.
Valuation
| ABBV | SPRY | |
|---|---|---|
| P/E Ratio | 72.45 | — |
| Price / Book | -76.97 | 44.67 |
| Price / Sales | 7.04 | 4.78 |
ABBV and SPRY split the valuation factors evenly.
Profitability
| ABBV | SPRY | |
|---|---|---|
| Net Margin | 9.81% | -184.24% |
| Return on Equity | -107.29% | -1721.80% |
ABBV leads on 2 of 2 profitability factors.
Dividend
| ABBV | SPRY | |
|---|---|---|
| Dividend Yield | 2.70% | — |
| Payout Ratio | 195.48 | — |
ABBV and SPRY split the dividend factors evenly.
Risk & Sentiment
| ABBV | SPRY | |
|---|---|---|
| Short Interest | 0.85% | 0.82% |
SPRY leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABBV overview, ABBV financials, SPRY overview, SPRY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.